These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 6127534)
21. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. Gualtieri F; Dei S; Manetti D; Romanelli MN; Scapecchi S; Teodori E Farmaco; 1995; 50(7-8):489-503. PubMed ID: 7669187 [No Abstract] [Full Text] [Related]
22. Muscarinic agonists for senile dementia: past experience and future trends. Gray JA; Enz A; Spiegel R Trends Pharmacol Sci; 1989 Dec; Suppl():85-8. PubMed ID: 2694530 [TBL] [Abstract][Full Text] [Related]
24. Double blind study of lecithin in patients with Alzheimer's disease. Fisman M; Merskey H; Helmes E; McCready J; Colhoun EH; Rylett BJ Can J Psychiatry; 1981 Oct; 26(6):426-8. PubMed ID: 7028239 [No Abstract] [Full Text] [Related]
25. Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. Volpato D; Holzgrabe U Molecules; 2018 Dec; 23(12):. PubMed ID: 30544533 [TBL] [Abstract][Full Text] [Related]
26. The use of cholinergic precursors in neuropsychiatric diseases. Rosenberg GS; Davis KL Am J Clin Nutr; 1982 Oct; 36(4):709-20. PubMed ID: 6214943 [TBL] [Abstract][Full Text] [Related]
27. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?]. Vamvakidès A Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934 [TBL] [Abstract][Full Text] [Related]
28. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Flynn DD; Weinstein DA; Mash DC Ann Neurol; 1991 Mar; 29(3):256-62. PubMed ID: 2042942 [TBL] [Abstract][Full Text] [Related]
29. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Nordberg A; Lundqvist H; Hartvig P; Andersson J; Johansson M; Hellstrŏm-Lindahi E; Långström B Dement Geriatr Cogn Disord; 1997; 8(2):78-84. PubMed ID: 9065319 [TBL] [Abstract][Full Text] [Related]
30. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Lemière J; Van Gool D; Dom R Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352 [TBL] [Abstract][Full Text] [Related]
31. [Pharmaceutical research strategies in Alzheimer's disease]. Wülfert E J Pharm Belg; 1991; 46(1):67-77. PubMed ID: 2051302 [TBL] [Abstract][Full Text] [Related]
32. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya. Mufson EJ; Jaffar S; Levey AI J Comp Neurol; 1998 Mar; 392(3):313-29. PubMed ID: 9511920 [TBL] [Abstract][Full Text] [Related]
34. The cholinergic system in old age and Alzheimer's disease. Perry EK Age Ageing; 1980 Feb; 9(1):1-8. PubMed ID: 7361631 [TBL] [Abstract][Full Text] [Related]
36. Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase. Fu AL; Li Q; Dong ZH; Huang SJ; Wang YX; Sun MJ Neurosci Lett; 2004 Sep; 368(3):258-62. PubMed ID: 15364407 [TBL] [Abstract][Full Text] [Related]
37. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Perry EK; Tomlinson BE; Blessed G; Bergmann K; Gibson PH; Perry RH Br Med J; 1978 Nov; 2(6150):1457-9. PubMed ID: 719462 [TBL] [Abstract][Full Text] [Related]